Editorial: Moving beyond the molecular mechanisms of malignant pleural mesothelioma: Cues for novel biomarkers and drug targets.
作者信息
Cavallari Ilaria, Cerciello Ferdinando, Giovannetti Elisa, Urso Loredana
机构信息
Immunology and Molecular Oncology Unit, Istituto Oncologico Veneto - Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), Padua, Italy.
Department of Medical Oncology, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland.
出版信息
Front Oncol. 2023 Mar 6;13:1163144. doi: 10.3389/fonc.2023.1163144. eCollection 2023.
Abstract
摘要
相似文献
1
Editorial: Moving beyond the molecular mechanisms of malignant pleural mesothelioma: Cues for novel biomarkers and drug targets.社论：超越恶性胸膜间皮瘤的分子机制：新型生物标志物和药物靶点的线索
Front Oncol. 2023 Mar 6;13:1163144. doi: 10.3389/fonc.2023.1163144. eCollection 2023.
2
Malignant pleural mesothelioma and mesothelial hyperplasia: A new molecular tool for the differential diagnosis.恶性胸膜间皮瘤和间皮增生：一种用于鉴别诊断的新分子工具。
Oncotarget. 2017 Jan 10;8(2):2758-2770. doi: 10.18632/oncotarget.13174.
3
Analysis of microRNA expression signatures in malignant pleural mesothelioma, pleural inflammation, and atypical mesothelial hyperplasia reveals common predictive tumorigenesis-related targets.恶性胸膜间皮瘤、胸膜炎症和非典型间皮增生中微小RNA表达特征分析揭示了常见的预测肿瘤发生相关靶点。
Exp Mol Pathol. 2014 Dec;97(3):375-85. doi: 10.1016/j.yexmp.2014.09.016. Epub 2014 Sep 16.
4
Genomics and Functional Genomics of Malignant Pleural Mesothelioma.恶性胸膜间皮瘤的基因组学和功能基因组学。
Int J Mol Sci. 2020 Sep 1;21(17):6342. doi: 10.3390/ijms21176342.
5
KCa1.1, a calcium-activated potassium channel subunit alpha 1, is targeted by miR-17-5p and modulates cell migration in malignant pleural mesothelioma.钾钙激活通道亚基α1（KCa1.1）是miR-17-5p的作用靶点，并调节恶性胸膜间皮瘤中的细胞迁移。
Mol Cancer. 2016 Jun 1;15(1):44. doi: 10.1186/s12943-016-0529-z.
6
Pleural effusion biomarkers and computed tomography findings in diagnosing malignant pleural mesothelioma: A retrospective study in a single center.用于诊断恶性胸膜间皮瘤的胸腔积液生物标志物及计算机断层扫描结果：一项单中心回顾性研究
PLoS One. 2017 Oct 2;12(10):e0185850. doi: 10.1371/journal.pone.0185850. eCollection 2017.
7
SORORIN and PLK1 as potential therapeutic targets in malignant pleural mesothelioma.SORORIN和PLK1作为恶性胸膜间皮瘤的潜在治疗靶点。
Int J Oncol. 2016 Dec;49(6):2411-2420. doi: 10.3892/ijo.2016.3765. Epub 2016 Nov 10.
8
Functional Analysis of the Adrenomedullin Pathway in Malignant Pleural Mesothelioma.肾上腺髓质素通路在恶性胸膜间皮瘤中的功能分析。
J Thorac Oncol. 2016 Jan;11(1):94-107. doi: 10.1016/j.jtho.2015.09.004.
9
A review of transcriptome studies combined with data mining reveals novel potential markers of malignant pleural mesothelioma.一项结合转录组研究和数据挖掘的综述揭示了恶性胸膜间皮瘤的新型潜在标志物。
Mutat Res. 2012 Apr-Jun;750(2):132-140. doi: 10.1016/j.mrrev.2011.12.003. Epub 2011 Dec 15.
10
Improved diagnosis and prognostication of patients with pleural malignant mesothelioma using biomarkers in pleural effusions and peripheral blood samples - a short report.采用胸腔积液和外周血样本中的生物标志物改善胸膜恶性间皮瘤患者的诊断和预后 - 一份简短报告。
Cell Oncol (Dordr). 2017 Oct;40(5):511-519. doi: 10.1007/s13402-017-0327-7. Epub 2017 Jun 2.
本文引用的文献
1
Global magnitude and temporal trend of mesothelioma burden along with the contribution of occupational asbestos exposure in 204 countries and territories from 1990 to 2019: Results from the Global Burden of Disease Study 2019.全球范围内 1990 年至 2019 年 204 个国家和地区间间皮瘤负担及其与职业性石棉暴露关联性的全球规模和时间趋势：来自 2019 年全球疾病负担研究的结果。
Crit Rev Oncol Hematol. 2022 Nov;179:103821. doi: 10.1016/j.critrevonc.2022.103821. Epub 2022 Sep 19.
2
New Era for Malignant Pleural Mesothelioma: Updates on Therapeutic Options.恶性胸膜间皮瘤的新纪元：治疗选择的最新进展。
J Clin Oncol. 2022 Feb 20;40(6):681-692. doi: 10.1200/JCO.21.01567. Epub 2022 Jan 5.
3
First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial.一线纳武利尤单抗联合伊匹单抗治疗不可切除恶性胸膜间皮瘤（CheckMate 743）：一项多中心、随机、开放标签、III 期临床试验。
Lancet. 2021 Jan 30;397(10272):375-386. doi: 10.1016/S0140-6736(20)32714-8. Epub 2021 Jan 21.
4
Epidemiology of mesothelioma in the 21 century in Europe and the United States, 40 years after restricted/banned asbestos use.在欧洲和美国限制/禁止使用石棉40年后，21世纪间皮瘤的流行病学情况
Transl Lung Cancer Res. 2020 Feb;9(Suppl 1):S28-S38. doi: 10.21037/tlcr.2019.11.11.
5
Thymidylate synthase and excision repair cross-complementing group-1 as predictors of responsiveness in mesothelioma patients treated with pemetrexed/carboplatin.胸苷酸合成酶和切除修复交叉互补组 1 作为预测培美曲塞/卡铂治疗间皮瘤患者反应的标志物。
Clin Cancer Res. 2011 Apr 15;17(8):2581-90. doi: 10.1158/1078-0432.CCR-10-2873. Epub 2011 Jan 24.
6
Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma.培美曲塞联合顺铂与顺铂单药治疗恶性胸膜间皮瘤患者的III期研究。
J Clin Oncol. 2003 Jul 15;21(14):2636-44. doi: 10.1200/JCO.2003.11.136.
Zotero 插件